Macrophage Migration Inhibitory Factor for Diagnosing Endometriosis and Its Severity

NCT ID: NCT04091997

Last Updated: 2019-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endometriosis is a chronic disease affecting women of reproductive age. Macrophage migration inhibitory factor (MIF) is one of non-invasive blood biomarker that was detected in sera of endometriotic patients.The aim of this study was to evaluate the value of serum macrophage migration inhibitory factor in diagnosing endometriosis in women with infertility and chronic pelvic pain and correlate its level with the stage of the disease. Three hundred patient candidate for diagnostic laparoscopy were included in a case-control observational study

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

observational case-control study conducted in Fayoum University hospital from March 2016 till September 2018. Three hundred women candidate for diagnostic laparoscopy for either infertility or gynecologic chronic pelvic pain were included. The study group included patients with diagnostic criteria of endometriosis. The control group included other causes of infertility or pelvic pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometriosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

endometriosis

laparoscopy and directed biopsy of lesions serum macrophage migration inhibitory factor ELIZA assay

serum Eliza assay

Intervention Type DIAGNOSTIC_TEST

laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor

control

diagnostic laparoscopy serum macrophage migration inhibitory factor ELIZA assay

serum Eliza assay

Intervention Type DIAGNOSTIC_TEST

laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

serum Eliza assay

laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

laparoscopy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* postmenstrual women
* in childbearing period,
* presenting with either gynecologic chronic pelvic pain (CPP) or infertility
* indicated and fit for diagnostic laparoscopy.
* All women must have no hormonal treatment for the last 3 months and.

Exclusion Criteria

* Women with bleeding tendency,
* suspicious of gynecologic malignancy or
* active infection
Minimum Eligible Age

19 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fayoum University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sahar MY Elbaradie

associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

fayoum UH

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Biomarkers in Endometriosis
NCT04591548 COMPLETED
Diagnosis of Pelvic Endometriosis in MRI
NCT06157528 NOT_YET_RECRUITING NA
PET/MRI for Evaluation of Endometriosis
NCT06377553 ENROLLING_BY_INVITATION